Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
DocMorris ( (CH:DOCM) ) has issued an announcement.
DocMorris AG successfully completed its rights offering, with 98.7% of subscription rights exercised, generating approximately CHF 200 million in gross proceeds. This capital increase aims to support the company’s growth in prescription drugs, marketing expenses, and potential bond repayment. The new shares will be listed on the SIX Swiss Exchange, enhancing DocMorris’s financial position and strategic growth plans.
The most recent analyst rating on (CH:DOCM) stock is a Sell with a CHF19.00 price target. To see the full list of analyst forecasts on DocMorris stock, see the CH:DOCM Stock Forecast page.
More about DocMorris
DocMorris AG is a prominent player in the online pharmacy, marketplace, and professional healthcare sectors, with a significant presence in Germany and other European countries. The company operates a highly automated logistics center in the Netherlands and leads the health and care product marketplace in Southern Europe. With a vision to create a digital health ecosystem, DocMorris serves over 10 million active customers and achieved external sales of CHF 1,085 million in 2024.
Average Trading Volume: 352,232
Current Market Cap: CHF449M
See more data about DOCM stock on TipRanks’ Stock Analysis page.